GlassScriptPhysician profile
Denis P Manor
NPI 1326085564
$4,416.84
in general payments reported to CMS, 2019-2025
28 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $143 · 2021: $201 · 2022: $397 · 2023: $997 · 2024: $633 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.21 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $573.24 | 2019-2024 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.67 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $455.83 | 2019-2025 | |
| Lilly USA, LLC | $322.53 | 2022-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $245.96 | 2022-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $245.92 | 2025 | Onpattro, Amvuttra |
| Pfizer INC. | $225.57 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $198.43 | 2022-2025 | Uptravi, Opsumit |
| Edwards Lifesciences Corporation | $184.95 | 2025 | |
| Scpharmaceuticals INC. | $154.97 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $143.19 | 2022-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $137.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $128.66 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $122.88 | 2025 | Ozempic |
| Boston Scientific Corporation | $119.04 | 2019-2023 | Watchman Access System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $117.14 | 2024-2025 | |
| Esperion Therapeutics, INC. | $114.99 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $71.41 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $62.06 | 2023-2024 | |
| Amgen INC. | $57.68 | 2020-2024 | Repatha |
| Cvrx, INC. | $49.01 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $33.39 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $23.62 | 2020 | |
| Bridgebio Pharma, INC. | $21.76 | 2025 | Attruby |
| Genzyme Corporation | $21.64 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.33 | 2025 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $16.60 | 2023 | Evkeeza |
| Gilead Sciences, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denis Manor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.